NDC 42291-300-18 - Gabapentin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 42291-300
- Requested NDC
- 42291-300-18
- Package NDCs from labels
- 42291-300-50, 42291-300-18
- Manufacturer
- AvKARE
- Effective date
- 2022-01-13
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Gabapentin - AvKARE | AvKARE | 2022-01-13 | HUMAN PRESCRIPTION DRUG LABEL |
| National Council for Prescription Drug Programs indexing - billing unit | National Council for Prescription Drug Programs | 2013-02-13 | Indexing - Billing Unit |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 42291-300-10 | EA - Each | 42291-300 | 5c2871aa-905f-41a6-bbd1-b1d511795efb | 1 | 2013-02-13 |
| 42291-300-18 | EA - Each | 42291-300 | f93a8097-a3fc-4094-9928-1d8dc1f4b3ff | 1 | 2013-02-13 |
| 42291-300-27 | EA - Each | 42291-300 | bbdabb19-ab3b-431f-bd23-0835bfba9a64 | 1 | 2013-02-13 |
| 42291-300-50 | EA - Each | 42291-300 | 4cd07640-6393-40d1-a357-e3afd2c2a6af | 1 | 2018-10-11 |
| 42291-300-90 | EA - Each | 42291-300 | 0243b5bf-5396-4442-8e56-5f5cd79a41e2 | 1 | 2013-02-13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 54c09aa5-6724-480a-a115-c88484e39e93 | 2026-02-24 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Advagen Pharma Ltd | 401b30fc-e143-4906-aae1-e5b5c190d4a8 | 2026-02-24 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Advagen Pharma Ltd | bfee67dc-d2b1-4a00-92d9-a42be3189c74 | 2026-02-24 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | PD-Rx Pharmaceuticals, Inc. | 9814b76c-87c6-4746-b712-3269352a901b | 2026-02-16 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | d8daa30f-1cb3-46aa-9b68-d9aa5b0a2105 | 2026-02-12 | Warnings, Adverse reactions | 310430 310432 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | c979f80b-d4b1-40f7-b878-b216db5f325d | 2026-02-10 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | b88b0cbc-c883-4d17-8f46-0e5bddc57835 | 2026-02-10 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 3dbd447f-4791-4c62-86b4-6f7928862785 | 2026-02-10 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 081fd1de-acaa-4685-a053-4959d77b17e9 | 2026-02-10 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 0e1d17d5-d39c-4144-aac0-7c0d3bc9ec0d | 2026-02-09 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 2343e3a1-82d0-4c70-a086-a01a0ce81ef3 | 2026-02-09 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 67330eef-c976-4862-b1ae-20f30f43df76 | 2026-02-09 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Bryant Ranch Prepack | 2e331641-ec26-4d76-b16b-a9863c767afe | 2026-02-06 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Bryant Ranch Prepack | cc1998a7-7004-4688-8b5b-525041851d1d | 2026-02-05 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | A-S Medication Solutions | 4aa69d04-6b32-4764-a48b-ef5313dd95d3 | 2026-01-23 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Preferred Pharmaceuticals Inc. | 60b46f6d-efbc-487a-b672-b20df8b44cc4 | 2026-01-23 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | A-S Medication Solutions | 43a3ec78-8235-4d46-a343-2f9226745a39 | 2026-01-23 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | A-S Medication Solutions | 685553b0-384e-400b-a8ae-612ceece8261 | 2026-01-22 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | A-S Medication Solutions | 7ea0b220-edbb-45eb-aeb3-65283f8489a1 | 2026-01-22 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals, Inc. | bff3beea-1f05-4e84-bcd2-d05782acddae | 2026-01-14 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.